2020
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
Anderson B, Danforth A, Daroff R, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden M, Dilley J, Mitchell J, Woolley J. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 2020, 27: 100538. PMID: 33150319, PMCID: PMC7599297, DOI: 10.1016/j.eclinm.2020.100538.Peer-Reviewed Original ResearchGroup therapyBaseline to end-of-treatmentUS Department of Veterans AffairsBaseline to 3-month follow-upRapid-acting treatmentDepartment of Veterans AffairsFeasibility pilot studyEnd-of-treatmentIntent-to-treat analysisClinically meaningful changeIndividual psychotherapyPsilocybin therapyOpen-label safetyPost-psilocybinTherapy visitsFollow-upPsychiatric needsAdverse reactionsVeterans AffairsParticipant recruitmentPsilocybinMedical illnessDemoralizationMeasures ANOVAMeaningful change
2017
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports 2017, 19: 74. PMID: 28844076, PMCID: PMC5904792, DOI: 10.1007/s11920-017-0829-z.Peer-Reviewed Original ResearchConceptsSynaptic connectivityRapid-acting treatmentPathophysiology of PTSDPotential clinical importanceTreatment of PTSDSynaptic lossPurpose of ReviewStudiesDisconnection syndromeClinical importanceNovel pharmacotherapeuticsNovel therapeuticsPTSD symptomsRecent FindingsHerePTSDPathophysiologyKetamineTreatmentDisordersTherapeutic applicationsStress-related lossesSyndromeSymptomsPharmacotherapeutics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply